Back to Search Start Over

Outcomes in Patients With Poststroke Seizures: A Systematic Review and Meta-Analysis.

Authors :
Misra S
Kasner SE
Dawson J
Tanaka T
Zhao Y
Zaveri HP
Eldem E
Vazquez J
Silva LS
Mohidat S
Hickman LB
Khan EI
Funaro MC
Nicolo JP
Mazumder R
Yasuda CL
Sunnerhagen KS
Ihara M
Ross JS
Liebeskind DS
Kwan P
Quinn TJ
Engel J Jr
Mishra NK
Source :
JAMA neurology [JAMA Neurol] 2023 Nov 01; Vol. 80 (11), pp. 1155-1165.
Publication Year :
2023

Abstract

Importance: Published data about the impact of poststroke seizures (PSSs) on the outcomes of patients with stroke are inconsistent and have not been systematically evaluated, to the authors' knowledge.<br />Objective: To investigate outcomes in people with PSS compared with people without PSS.<br />Data Sources: MEDLINE, Embase, PsycInfo, Cochrane, LILACS, LIPECS, and Web of Science, with years searched from 1951 to January 30, 2023.<br />Study Selection: Observational studies that reported PSS outcomes.<br />Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist was used for abstracting data, and the Joanna Briggs Institute tool was used for risk-of-bias assessment. Data were reported as odds ratio (OR) and standardized mean difference (SMD) with a 95% CI using a random-effects meta-analysis. Publication bias was assessed using funnel plots and the Egger test. Outlier and meta-regression analyses were performed to explore the source of heterogeneity. Data were analyzed from November 2022 to January 2023.<br />Main Outcomes and Measures: Measured outcomes were mortality, poor functional outcome (modified Rankin scale [mRS] score 3-6), disability (mean mRS score), recurrent stroke, and dementia at patient follow-up.<br />Results: The search yielded 71 eligible articles, including 20 110 patients with PSS and 1 166 085 patients without PSS. Of the participants with PSS, 1967 (9.8%) had early seizures, and 10 605 (52.7%) had late seizures. The risk of bias was high in 5 studies (7.0%), moderate in 35 (49.3%), and low in 31 (43.7%). PSSs were associated with mortality risk (OR, 2.1; 95% CI, 1.8-2.4), poor functional outcome (OR, 2.2; 95% CI, 1.8-2.8), greater disability (SMD, 0.6; 95% CI, 0.4-0.7), and increased dementia risk (OR, 3.1; 95% CI, 1.3-7.7) compared with patients without PSS. In subgroup analyses, early seizures but not late seizures were associated with mortality (OR, 2.4; 95% CI, 1.9-2.9 vs OR, 1.2; 95% CI, 0.8-2.0) and both ischemic and hemorrhagic stroke subtypes were associated with mortality (OR, 2.2; 95% CI, 1.8-2.7 vs OR, 1.4; 95% CI, 1.0-1.8). In addition, early and late seizures (OR, 2.4; 95% CI, 1.6-3.4 vs OR, 2.7; 95% CI, 1.8-4.1) and stroke subtypes were associated with poor outcomes (OR, 2.6; 95% CI, 1.9-3.7 vs OR, 1.9; 95% CI, 1.0-3.6).<br />Conclusions and Relevance: Results of this systematic review and meta-analysis suggest that PSSs were associated with significantly increased mortality and severe disability in patients with history of stroke. Unraveling these associations is a high clinical and research priority. Trials of interventions to prevent seizures may be warranted.

Details

Language :
English
ISSN :
2168-6157
Volume :
80
Issue :
11
Database :
MEDLINE
Journal :
JAMA neurology
Publication Type :
Academic Journal
Accession number :
37721736
Full Text :
https://doi.org/10.1001/jamaneurol.2023.3240